```html

Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Overview

Wegener’s granulomatosis—now officially called granulomatosis with polyangiitis (GPA)—is a rare, systemic autoimmune disease that causes inflammation of blood vessels (vasculitis) and the formation of granulomas, which are clusters of inflammatory cells. The disease most commonly affects the upper and lower respiratory tract and the kidneys, but it can involve virtually any organ.

Who it affects: GPA typically presents in adults between the ages of 40 and 65, and it is slightly more common in men than women. However, it can occur at any age, including childhood.

Prevalence: In the United States, the incidence is about 12–25 cases per million people per year, and the prevalence is roughly 150–200 cases per million [1][2]. The disease is considered rare worldwide, with similar rates reported in Europe and Asia.

Symptoms

Because GPA can involve many organ systems, symptoms are often variable and may develop rapidly over weeks or months. Below is a comprehensive list, grouped by the organ system most commonly affected.

Upper Respiratory Tract

• Chronic sinusitis – persistent nasal congestion, facial pain, and post‑nasal drip.
• Nasal crusting or bleeding (epistaxis) – may be recurrent.
• Saddle‑nose deformity – collapse of the nasal bridge due to cartilage destruction.
• Ear pain or hearing loss – caused by middle‑ear involvement.

Lower Respiratory Tract

• Cough – may be dry or produce sputum.
• Shortness of breath – due to lung nodules, infiltrates, or alveolar hemorrhage.
• Chest pain – pleuritic pain is possible.
• Hemoptysis – coughing up blood, a red‑flag sign.

Renal (Kidney) Involvement

• Hematuria – blood in the urine, often microscopic.
• Proteinuria – excess protein in urine.
• Decreased urine output or swelling (edema) in legs and ankles.

General/Systemic Features

• Fever – low‑grade or persistent.
• Fatigue – profound, often out of proportion to activity level.
• Weight loss – unintended, over weeks to months.
• Joint or muscle pain – arthralgia without swelling is common.
• Skin lesions – palpable purpura, ulcers, or nodules.

Other Possible Manifestations

• Eye involvement – redness, pain, vision changes due to scleritis or orbital inflammation.
• Neurologic symptoms – peripheral neuropathy, cranial nerve palsies.
• Gastrointestinal complaints – abdominal pain, melena if the GI tract is involved.

Causes and Risk Factors

The exact trigger for GPA remains unknown, but research points to a combination of genetic predisposition and environmental factors that lead to an abnormal immune response.

Autoimmune Mechanism

• Anti‑neutrophil cytoplasmic antibodies (ANCA) – most patients have cytoplasmic‑ANCA (c‑ANCA) directed against proteinase‑3 (PR3). These antibodies activate neutrophils, causing them to release enzymes that damage vessel walls [3].

Genetic Susceptibility

• Specific HLA alleles (e.g., HLA‑DPB1*04) and genes involved in immune regulation increase risk, but no single gene is determinative.

Environmental Triggers

• Silica dust exposure – reported more often in occupational settings like mining or construction.
• Infections – hypotheses include chronic bacterial or viral infections acting as a “second hit,” though definitive proof is lacking.

Who Is At Higher Risk?

• Adults 40–65 years old.
• Male gender (slightly higher incidence).
• People with a family history of autoimmune disease.
• Individuals with occupational silica exposure.

Diagnosis

Diagnosing GPA requires a combination of clinical assessment, laboratory testing, imaging, and often tissue biopsy. Early recognition is crucial to prevent irreversible organ damage.

Clinical Evaluation

• Detailed history and physical exam focusing on ENT, pulmonary, renal, and skin findings.

Laboratory Tests

• ANCA testing – c‑ANCA (PR3‑ANCA) is positive in 80–90% of active GPA cases; p‑ANCA (MPO‑ANCA) may be present in a minority.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Renal function panel – serum creatinine, BUN, electrolytes.
• Urinalysis – hematuria, proteinuria, red‑cell casts.
• Inflammatory markers – ESR and CRP are usually elevated.

Imaging Studies

• Chest X‑ray – can reveal nodules, cavitations, or infiltrates.
• High‑resolution CT (HRCT) of the chest – provides detailed view of pulmonary lesions.
• Sinus CT – assesses chronic sinusitis, bony destruction.

Biopsy

• Gold standard for confirmation. Typical findings include necrotizing granulomas, vasculitis of small‑ to medium‑size vessels, and necrotizing glomerulonephritis when kidney tissue is sampled.
• Common biopsy sites: nasal mucosa, lung, or kidney (if renal involvement is suspected).

Diagnostic Criteria

The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria assign points to clinical features, ANCA status, and histology. A total score ≥5 classifies a patient as having GPA [4].

Treatment Options

Treatment aims to induce remission, then maintain it while minimizing drug toxicity. Therapy is individualized based on disease severity, organ involvement, and patient factors.

Induction Therapy (Rapid disease control)

Regimen	Typical Duration	Key Points
High‑dose glucocorticoids (e.g., methylprednisolone 1 mg/kg/day)	4‑6 weeks, then taper	Rapid anti‑inflammatory effect; monitor blood glucose, bone health.
Cyclophosphamide (IV pulse 15 mg/kg or oral 2 mg/kg/day)	3‑6 months	Best for severe organ involvement; risks include cytopenias, bladder toxicity, infertility.
Rituximab (375 mg/m² weekly ×4 or 1 g on day 0 & 15)	4‑6 weeks induction	Non‑alkylating alternative; preferred for patients desiring fertility preservation or with cyclophosphamide contraindications.

Maintenance Therapy (Prevent relapse)

• Azathioprine (2 mg/kg/day) – commonly used after cyclophosphamide induction.
• Mycophenolate mofetil (1‑1.5 g twice daily) – an alternative, especially if azathioprine is not tolerated.
• Low‑dose glucocorticoids – usually 5–10 mg prednisone daily, tapered over months.
• Rituximab – repeat dosing (e.g., 500 mg every 6 months) is increasingly favored for long‑term control.

Adjunctive Measures

• Proton‑pump inhibitors – protect stomach lining while on steroids.
• Calcium & vitamin D supplementation – reduce osteoporosis risk.
• Vaccinations – influenza annually, pneumococcal, COVID‑19, and hepatitis B per CDC guidelines before immunosuppression.
• Infection prophylaxis – trimethoprim‑sulfamethoxazole for Pneumocystis pneumonia in patients on high‑dose steroids or cyclophosphamide.

Procedural Interventions

• Plasma exchange (PLEX) – considered for severe renal disease or diffuse alveolar hemorrhage, though recent trials show mixed benefit.
• Surgical debridement – may be needed for necrotic sinus disease or airway obstruction.

Living with Wegener’s Granulomatosis

Managing GPA is a lifelong partnership between the patient, rheumatologist, and other specialists (nephrologist, pulmonologist, ENT surgeon, etc.). Below are practical tips to help maintain health and quality of life.

Medication Management

• Use a weekly pill organizer and set alarms for dosing.
• Keep a medication list (including doses) handy for every medical visit.
• Never stop steroids abruptly; taper under physician supervision.

Monitoring & Follow‑up

• Laboratory checks every 2–4 weeks during induction (CBC, renal panel, ANCA levels).
• After remission, labs every 3‑6 months; watch for rising creatinine or new anemia.
• Annual ophthalmology exam if on long‑term steroids.
• Bone density scan (DEXA) every 1–2 years.

Lifestyle & Self‑Care

• Healthy diet – high in fruits, vegetables, lean protein; limit sodium to protect kidneys.
• Exercise – low‑impact activities (walking, swimming) improve stamina and bone health.
• Stress reduction – mindfulness, yoga, or counseling can help manage fatigue and mood swings.
• Smoking cessation – essential; smoking worsens lung involvement.
• Hydration – adequate fluid intake supports kidney function, unless fluid restriction is ordered for severe renal disease.

Support Resources

• American Vasculitis Foundation (AVF) – patient education, support groups.
• National Organization for Rare Disorders (NORD) – insurance assistance.
• Online communities (e.g., Reddit r/vasculitis) – peer experiences.

Prevention

Because GPA is an autoimmune disease with unknown primary cause, true primary prevention is not possible. However, certain measures can lower the risk of disease flare or secondary complications.

• Avoid occupational silica exposure; use protective equipment if exposure is unavoidable.
• Stay up‑to‑date with vaccinations before starting immunosuppressive therapy.
• Promptly treat infections; seek medical advice early for fevers or respiratory symptoms.
• Limit alcohol and avoid recreational drugs that can exacerbate liver toxicity when on certain medications.

Complications

If untreated or inadequately controlled, GPA can lead to serious, sometimes life‑threatening consequences.

• Renal failure – rapidly progressive glomerulonephritis may require dialysis or transplantation.
• Diffuse alveolar hemorrhage – massive lung bleeding causing respiratory failure.
• Permanent sinus or airway damage – leading to chronic infections or obstructive sleep apnea.
• Peripheral neuropathy – loss of sensation or motor function.
• Secondary infections – due to immunosuppression (e.g., opportunistic fungal or viral infections).
• Medication toxicity – bladder cancer from cyclophosphamide, bone marrow suppression, or liver injury.
• Thromboembolic events – increased risk of deep‑vein thrombosis and pulmonary embolism.

When to Seek Emergency Care

References

1. Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). 2023. https://www.mayoclinic.org.
2. CDC. Vasculitis: Epidemiology and Risk Factors. 2022. https://www.cdc.gov.
3. Jennette JC, et al. ANCA‑associated vasculitis. New England Journal of Medicine. 2020;382: 425‑439.
4. Yates M, et al. 2022 ACR/EULAR classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatology. 2022;74:1234‑1245.
5. Brown KM, et al. Management of granulomatosis with polyangiitis: 2023 update. Cleveland Clinic Journal of Medicine. 2023;90(7): 417‑426.

```